Par Launches Potassium Chloride ER Caps
Par announced it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Potassium Chloride Extended-Release (ER) Capsules.
Par announced it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Potassium Chloride Extended-Release (ER) Capsules.
The USPSTF has found that insufficient evidence to evaluate the benefits and harms of multivitamins and most single- or paired-nutrient supplements for the prevention of cardiovascular disease and cancer.
Quality, patient outcomes, and costs must all be assessed in determining the appropriateness of noninvasive cardiovascular imaging.
Cardiac drug interactions make up almost 25% of all preventable adverse drug reactions.
Fewer than half of Americans are aware that body weight and physical activity affect cancer risk.
Patients with adrenal tumors of intermediate phenotype or subclinical Cushing’s syndrome are at increased risk of cardiovascular events and mortality compared to those with stable non-secreting adrenal incidentalomas.
First trimester fetal growth restriction correlates with an adverse cardiovascular risk profile in childhood.
ZS Pharma announced top-line results from its Extended Treatment Phase of ZS003, a Phase 3 trial of ZS-9 for the treatment of hyperkalemia.
For children requiring maintenance intravenous (IV) fluids, isotonic fluids are safer than hypotonic fluids in terms of plasma sodium (pNa) levels.
ZS Pharma has announced top-line results from the acute phase of its pivotal Phase 3 ZS-003 trial of ZS-9, an investigational treatment for hyperkalemia.